VECT News and Press, VectivBio Holding AG From 06/08/23

NEW YORK, NY / ACCESSWIRE / June 8, 2023 / June Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Home Point Capital Inc. (NASDAQ:HMPT...

NEW YORK, NY / ACCESSWIRE / May 31, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Radius Global Infrastructure, Inc. (NASDA...

NEW YORK, NY / ACCESSWIRE / May 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Radius Global Infrastructure, Inc. ...

2023-05-22 17:43:00 ET Ironwood Pharmaceuticals (NASDAQ: IRWD) is choosing to go the acquisition route to grow its business. On Monday, the company announced it has agreed to acquire clinical-stage biotech VectivBio Holding (NASDAQ: VECT) . Investors were clearly warm to tha...

2023-05-22 12:02:21 ET Shares of VectivBio Holdings (NASDAQ: VECT) were up more than 35% Monday morning after the clinical-stage biotech company received a buyout offer from Ironwood Pharmaceuticals (NASDAQ: IRWD) . VectivBio's shares are up more than 85% so far this...

2023-05-22 10:03:29 ET Gainers: Microbot Medical ( MBOT ) +46% . Hepion Pharmaceuticals ( HEPA ) +41% . Atea Pharmaceuticals ( AVIR ) +38% . VectivBio Holding ( VECT ) +37% . CNS Pharmaceuticals ( CNSP ) +23% . Losers: Rain Oncology ( ...

2023-04-19 14:18:07 ET VectivBio Holding AG (VECT) Q4 2022 Earnings Conference Call April 19, 2023, 08:00 AM ET Company Participants Patrick Malloy - SVP, IR Luca Santarelli - CEO Claudia D'Augusta - CFO Omar Khwaja - Chief Medical Officer Kevin Harris - ...

2023-04-19 09:05:33 ET VectivBio press release ( NASDAQ: VECT ): FY GAAP EPS of -$2.12. Revenue of $27.3M. Research and development expenses: Research and development expenses were $74.0 million for the year ended December 31, 2022, as compared to $50.2 million for yea...

2023-04-19 07:09:15 ET VectivBio press release ( NASDAQ: VECT ): FY GAAP EPS of -$2.12 misses by $0.17 . Revenue of $27.3M beats by $6.57M . Cash and cash equivalents were $221.4 million as of December 31, 2022, compared to $102.7 million as of December 31, 202...

Continued Strong Progress and Momentum Across Multiple Programs with Key Upcoming Data Milestones Beginning Q2 2023 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) to Complete Enrollment this Quarter Interim Results of STARGAZE P...